ValiRx’s (LON:VAL) lead drug candidate may have an important role to play in the treatment of refractory prostate cancer.
This was one of the conclusions of a review by independent experts carried in the journal European Oncology & Haematology.
It considered the potential of new pipeline therapeutics such as ValiRx’s VAL201 alongside the current gold standard treatment docetaxel.
VAL201 is currently undergoing late stage preclinical and toxicology studies before entering clinical trials.
ValiRx chief executive Dr Satu Vainikka said: “I am delighted with the progress we are seeing in the development of VAL201 and am grateful for the endorsement this review represents.
“The market for treatments against hormone induced tumour growth and associated conditions is significant and these conditions have significant unmet clinical need.
“I am also delighted to see our new website launched and hope it will aid communication with our investors and all audiences as we approach an exciting new chapter in the company’s development.”